Breaking News, Collaborations & Alliances

Emergent BioSolutions, Novavax Enter COVID-19 Pact

Sign development and manufacturing agreement for experimental vaccine candidate for coronavirus disease

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Emergent BioSolutions has entered into a COVID-19 agreement with Novavax. It will collaborate with Novavax, utilizing its molecule-to-market contract development and manufacturing (CDMO) services to support bringing into the clinic Novavax’s novel experimental vaccine candidate to protect against coronavirus disease (COVID-19).   Emergent will produce the COVID-19 experimental vaccine candidate, which is based on the proprietary recombinant protein nanoparticle technology platform of Novavax and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters